News

Two mutations in the BRCA1 gene greatly increase the risk of breast cancer. Now, it seems that only one mutation can help cells tip toward a cancerous edge. ​

Researchers developed a new pill with promising applications for treating pain due to gastrointestinal disorders.

Industry leaders name the clinical trials and developments they’re most excited to see in the new year.

A small percentage of cells in healthy breast tissue show chromosomal abnormalities often linked to cancer, a finding with potential diagnostic implications.

New data show that NK cell engagers may provide a robust alternative to T cell therapies.

Industry leaders predict the most exciting advances in drug discovery and development in the coming year.

Genetic analysis of organoids and brain tumors showed that the cancers are packed with cells that haven’t reached a mature state.

An oligonucleotide transport vehicle could transform neurological disease treatment by enhancing drug delivery across the blood-brain barrier.

The FDA approved two new medications for Niemann-Pick disease type C that improve symptoms, showing the power of community advocacy.

New research revealed that manufacturer-funded clinical trials deem drugs more effective than non-sponsored trials.

Initially thought of as a DNA-damaging drug, 5-fluorouracil mainly kills cancer cells by interfering with ribosomal RNA, opening up new avenues for care. 

Bristol Myers Squibb unveiled promising CAR T cell therapy data for severe autoimmune diseases from their Phase 1 clinical trial, offering hope for remission.

Sulopenem becomes the first oral penem antibiotic approved in the United States, expanding non-IV treatment options for UTIs.

Researchers discovered that a blood clotting protein, fibrinogen, harms brain development during bleeds in preterm infants.

New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.

In some kids, an RSV infection is mild, while others are hospitalized. Natural killer cells might be the reason why.

Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.

Injectable micelles that release glucagon could provide a new way to treat hypoglycemic events in diabetes.

The link between metabolism and sleep is helping scientists find new biomarkers to detect sleepless nights and diagnose chronic sleep disorders.

Structural analysis of the herpes simplex virus polymerase revealed that mutations affecting its drug binding and flexibility may drive treatment resistance.